# Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

> **NCT03252808** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Takara Bio Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Pancreatic Cancer Stage III
- Pancreatic Cancer Stage IV

## Interventions

- **BIOLOGICAL:** TBI-1401(HF10)
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** TS-1

## Key facts

- **NCT ID:** NCT03252808
- **Lead sponsor:** Takara Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-25
- **Primary completion:** 2020-02-19
- **Final completion:** 2035-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252808, "Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03252808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*